Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer

NCT02404935 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02404935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02404935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2013
Completion date
October 25, 2021
Enrollment
139 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer